Esperion Therapeutics Flags Material Weakness in Financial Controls, Raising Reporting and Regulatory Risks

Esperion Therapeutics (ESPR) has disclosed a new risk, in the Accounting & Financial Operations category.

Esperion Therapeutics faces heightened reporting risk after management and its principal officers concluded that disclosure controls were not effective as of December 31, 2025, due to a material weakness in internal control over financial reporting tied to inventory at a third-party manufacturer. Although remediation steps and enhanced controls have been initiated, the weakness is not yet fully remediated, leaving ongoing risk of material misstatements, potential filing delays, regulatory scrutiny, and erosion of investor confidence.

Overall, Wall Street has a Moderate Buy consensus rating on ESPR stock based on 4 Buys, 1 Sell and 1 Hold.

To learn more about Esperion Therapeutics’ risk factors, click here.